tetano
Editor, Senior Moderator
Vaccine
. 2023 Apr 10;S0264-410X(23)00390-0.
doi: 10.1016/j.vaccine.2023.04.006. Online ahead of print.
Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus
Chi-Chieh Chang[SUP] 1 [/SUP], Abdullah Algaissi[SUP] 2 [/SUP], Chia-Chun Lai[SUP] 3 [/SUP], Chun-Kai Chang[SUP] 4 [/SUP], Jr-Shiuan Lin[SUP] 5 [/SUP], Yi-Shiang Wang[SUP] 1 [/SUP], Bo-Hau Chang[SUP] 1 [/SUP], Yu-Chiuan Chang[SUP] 1 [/SUP], Wei-Ting Chen[SUP] 6 [/SUP], Yong-Qing Fan[SUP] 1 [/SUP], Bi-Hung Peng[SUP] 7 [/SUP], Chih-Yu Chao[SUP] 6 [/SUP], Shiou-Ru Tzeng[SUP] 1 [/SUP], Pi-Hui Liang[SUP] 4 [/SUP], Wang-Chou Sung[SUP] 8 [/SUP], Alan Yung-Chih Hu[SUP] 8 [/SUP], Shin C Chang[SUP] 9 [/SUP], Ming-Fu Chang[SUP] 10 [/SUP]
Affiliations
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks have constituted a public health issue with drastic mortality higher than 34%, necessitating the development of an effective vaccine. During MERS-CoV infection, the trimeric spike protein on the viral envelope is primarily responsible for attachment to host cellular receptor, dipeptidyl peptidase 4 (DPP4). With the goal of generating a protein-based prophylactic, we designed a subunit vaccine comprising the recombinant S1 protein with a trimerization motif (S1-Fd) and examined its immunogenicity and protective immune responses in combination with various adjuvants. We found that sera from immunized wild-type and human DPP4 transgenic mice contained S1-specific antibodies that can neutralize MERS-CoV infection in susceptible cells. Vaccination with S1-Fd protein in combination with a saponin-based QS-21 adjuvant provided long-term humoral as well as cellular immunity in mice. Our findings highlight the significance of the trimeric S1 protein in the development of MERS-CoV vaccines and offer a suitable adjuvant, QS-21, to induce robust and prolonged memory T cell response.
Keywords: Adjuvant effects; Cellular immunity; MERS-CoV neutralization; Subunit vaccine development.
. 2023 Apr 10;S0264-410X(23)00390-0.
doi: 10.1016/j.vaccine.2023.04.006. Online ahead of print.
Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus
Chi-Chieh Chang[SUP] 1 [/SUP], Abdullah Algaissi[SUP] 2 [/SUP], Chia-Chun Lai[SUP] 3 [/SUP], Chun-Kai Chang[SUP] 4 [/SUP], Jr-Shiuan Lin[SUP] 5 [/SUP], Yi-Shiang Wang[SUP] 1 [/SUP], Bo-Hau Chang[SUP] 1 [/SUP], Yu-Chiuan Chang[SUP] 1 [/SUP], Wei-Ting Chen[SUP] 6 [/SUP], Yong-Qing Fan[SUP] 1 [/SUP], Bi-Hung Peng[SUP] 7 [/SUP], Chih-Yu Chao[SUP] 6 [/SUP], Shiou-Ru Tzeng[SUP] 1 [/SUP], Pi-Hui Liang[SUP] 4 [/SUP], Wang-Chou Sung[SUP] 8 [/SUP], Alan Yung-Chih Hu[SUP] 8 [/SUP], Shin C Chang[SUP] 9 [/SUP], Ming-Fu Chang[SUP] 10 [/SUP]
Affiliations
- PMID: 37085450
- PMCID: PMC10083212
- DOI: 10.1016/j.vaccine.2023.04.006
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks have constituted a public health issue with drastic mortality higher than 34%, necessitating the development of an effective vaccine. During MERS-CoV infection, the trimeric spike protein on the viral envelope is primarily responsible for attachment to host cellular receptor, dipeptidyl peptidase 4 (DPP4). With the goal of generating a protein-based prophylactic, we designed a subunit vaccine comprising the recombinant S1 protein with a trimerization motif (S1-Fd) and examined its immunogenicity and protective immune responses in combination with various adjuvants. We found that sera from immunized wild-type and human DPP4 transgenic mice contained S1-specific antibodies that can neutralize MERS-CoV infection in susceptible cells. Vaccination with S1-Fd protein in combination with a saponin-based QS-21 adjuvant provided long-term humoral as well as cellular immunity in mice. Our findings highlight the significance of the trimeric S1 protein in the development of MERS-CoV vaccines and offer a suitable adjuvant, QS-21, to induce robust and prolonged memory T cell response.
Keywords: Adjuvant effects; Cellular immunity; MERS-CoV neutralization; Subunit vaccine development.